Catalyst Pharmaceuticals, Inc. CPRX
We take great care to ensure that the data presented and summarized in this overview for CATALYST PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CPRX
View all-
Black Rock Inc. New York, NY18.7MShares$433 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.71MShares$202 Million0.0% of portfolio
-
State Street Corp Boston, MA6.41MShares$148 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4.97MShares$115 Million1.82% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.54MShares$82.2 Million0.1% of portfolio
-
Terry Smith Fundsmith LLP | London, X03.36MShares$78 Million0.34% of portfolio
-
Geode Capital Management, LLC Boston, MA2.89MShares$67 Million0.0% of portfolio
-
American Century Companies Inc Kansas City, MO2.53MShares$58.6 Million0.03% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.46MShares$57 Million0.01% of portfolio
-
Bank Of America Corp Charlotte, NC2.29MShares$53.1 Million0.0% of portfolio
Latest Institutional Activity in CPRX
Top Purchases
Top Sells
About CPRX
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Insider Transactions at CPRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 05
2026
|
Richard J Daly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,577
-3.75%
|
-
|
|
Jan 05
2026
|
Richard J Daly President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
42,105
+13.0%
|
-
|
|
Jan 05
2026
|
Michael Wayne Kalb Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,080
-13.21%
|
-
|
|
Jan 05
2026
|
Michael Wayne Kalb Executive Vice President & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,139
+31.2%
|
-
|
|
Dec 29
2025
|
Jeffrey Del Carmen Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,839
-21.12%
|
-
|
|
Dec 29
2025
|
Jeffrey Del Carmen Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,667
+32.29%
|
-
|
|
Dec 29
2025
|
Richard J Daly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
524
-0.22%
|
-
|
|
Dec 29
2025
|
Richard J Daly President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,334
+0.55%
|
-
|
|
Dec 29
2025
|
Patrick J Mcenany Director |
SELL
Payment of exercise price or tax liability
|
Direct |
6,786
-0.16%
|
-
|
|
Dec 29
2025
|
Patrick J Mcenany Director |
BUY
Exercise of conversion of derivative security
|
Direct |
26,334
+0.63%
|
-
|
|
Dec 29
2025
|
Molly Harper Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,334
+26.53%
|
-
|
|
Dec 29
2025
|
Steve Miller Chief Op. & Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,000
+1.26%
|
-
|
|
Dec 29
2025
|
Preethi Sundaram Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,369
-4.14%
|
-
|
|
Dec 29
2025
|
Preethi Sundaram Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,667
+10.44%
|
-
|
|
Dec 29
2025
|
David S Tierney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,334
+0.35%
|
-
|
|
Dec 29
2025
|
Brian Elsbernd Chief Compliance/Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,623
-1.07%
|
-
|
|
Dec 29
2025
|
Brian Elsbernd Chief Compliance/Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,667
+2.65%
|
-
|
|
Dec 29
2025
|
Donald A Denkhaus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,334
+0.27%
|
-
|
|
Dec 12
2025
|
Molly Harper Director |
SELL
Open market or private sale
|
Direct |
26,746
-53.46%
|
$615,158
$23.33 P/Share
|
|
Dec 12
2025
|
Molly Harper Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+40.73%
|
$100,000
$5.78 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 1.35M shares |
|---|---|
| Open market or private sale | 110K shares |
| Payment of exercise price or tax liability | 66.6K shares |
|---|---|
| Open market or private sale | 1.05M shares |
| Bona fide gift | 135K shares |